Beth JD - Xeris Pharmaceuticals Chief Secretary

Xeris Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (0.087) % which means that it has lost $0.087 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.1716) %, meaning that it created substantial loss on money invested by shareholders. Xeris Pharmaceuticals' management efficiency ratios could be used to measure how well Xeris Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 8.67 in 2025, whereas Return On Tangible Assets are likely to drop (0.31) in 2025. At this time, Xeris Pharmaceuticals' Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 5.5 M in 2025, despite the fact that Net Tangible Assets are likely to grow to (84 M).

Similar Executives

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. Xeris Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 294 people. Xeris Pharmaceuticals (XERS) is traded on NASDAQ Exchange in USA. It is located in 180 North LaSalle Street, Chicago, IL, United States, 60601 and employs 377 people. Xeris Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Xeris Pharmaceuticals Leadership Team

Xeris Stock Performance Indicators

Additional Tools for Xeris Stock Analysis